Calhoun D L, Waskin H, White M P, Bonner J R, Mulholland J H, Rumans L W, Stevens D A, Galgiani J N
Medical Service, Veterans Affairs Medical Center, Tucson, Arizona 85723.
Rev Infect Dis. 1991 Jan-Feb;13(1):47-51. doi: 10.1093/clinids/13.1.47.
Infections of deep soft tissues with the dimorphic fungus Sporothrix schenckii are uncommon in humans, and therapy has often required toxic drugs. We report our experience in treating 11 patients who had deep-seated sporotrichosis with ketoconazole, a well-tolerated, orally absorbed antifungal agent. Eight infections involved one or more joints, and three involved thoracic, cervical, and widespread cutaneous sites, respectively. For eight patients all evidence of infection resolved during therapy. Sustained remissions (6 months to 5 years) were noted for six patients after the discontinuation of all therapy and for an additional patient 4 years after the initiation of ketoconazole treatment. Durable responses were associated with prolonged treatment with 400-800 mg of ketoconazole daily. Our favorable experience suggests that oral therapy with ketoconazole may benefit other patients with systemic sporotrichosis.
由双相真菌申克孢子丝菌引起的深部软组织感染在人类中并不常见，治疗通常需要使用毒性药物。我们报告了使用酮康唑治疗11例深部孢子丝菌病患者的经验，酮康唑是一种耐受性良好、可口服吸收的抗真菌药物。8例感染累及一个或多个关节，3例分别累及胸部、颈部和广泛的皮肤部位。8例患者在治疗期间所有感染迹象均消失。6例患者在停止所有治疗后持续缓解（6个月至5年），另有1例患者在开始酮康唑治疗4年后缓解。持久反应与每日400 - 800毫克酮康唑的长期治疗有关。我们的良好经验表明，酮康唑口服治疗可能使其他系统性孢子丝菌病患者受益。
